• ქართული
  • English
  • Novartis hands investors Alcon spin-off and $5 billion share buyback

    ZURICH (Reuters) – Novartis plans to spin off its Alcon eye care business to shareholders and repurchase up to $5 billion in shares, as Chief Executive Vas Narasimhan refocuses the Swiss firm on prescription drugs.

    Market Quotes by TradingView